Semaglutide vs Tirzepatide: Which Is Better? [2026]

Last updated: April 2026

Medical Disclaimer: Informational only. Consult your healthcare provider before starting, stopping, or changing any medication.

Affiliate Disclosure: Some links may earn a commission. Editorial picks remain independent.

Semaglutide vs Tirzepatide at a Glance

Feature	Semaglutide (Wegovy)	Tirzepatide (Zepbound)	Verdict
Mechanism	GLP-1 agonist	Dual GLP-1 + GIP agonist	Tirzepatide adds GIP
Trial weight loss	14.9% (STEP-1, 68 wk)	20.9% (SURMOUNT-1, 72 wk)	Tirzepatide larger
Head-to-head	13.7% (SURMOUNT-5)	20.2% (SURMOUNT-5)	Tirzepatide wins direct
List price	$1,350-$1,400/mo	$1,060-$1,300/mo	Tirzepatide slightly lower
Cash-pay (manufacturer)	$349-$499 (NovoCare)	$399-$549 (LillyDirect)	Both accessible
FDA approval	Wegovy 2021 (obesity)	Zepbound 2023 (obesity), 2024 (OSA)	Best for
Dosing	Weekly injection (0.25-2.4 mg)	Weekly injection (2.5-15 mg)	Equivalent

Sources: STEP-1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), SURMOUNT-5 (NEJM 2024), manufacturer pricing pages April 2026.

The question of semaglutide vs tirzepatide has dominated weight management talk since tirzepatide's FDA approval for obesity in late 2023. Two injectables, two overlapping mechanisms, two different results on paper.

"Better" is rarely simple in medicine. Cost, side effects, insurance coverage, and individual biology all shape the real-world answer. This review compiles the best available clinical evidence as of 2026, including STEP, SURMOUNT, and SURMOUNT-5 data.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone your body makes after meals. The drug tells your brain you are full, slows the stomach, and cuts a sugar-raising hormone called glucagon.

Novo Nordisk developed it. It is sold under several brand names:

• Ozempic — injectable semaglutide, FDA-approved for type 2 diabetes (2017).
• Wegovy — injectable at higher dose (2.4 mg weekly), FDA-approved for chronic weight management in adults with obesity (2021).
• Rybelsus — oral semaglutide, FDA-approved for type 2 diabetes; not approved for weight management.

For weight loss comparison, Wegovy (2.4 mg weekly injectable) is the relevant formulation.

How Semaglutide Works

Semaglutide acts on GLP-1 receptors in the brain's hunger center. It does not just cut appetite. It also makes rich foods feel less rewarding.

It slows gastric emptying. Food stays in your stomach longer. Fullness lasts longer between meals.

Semaglutide is a once-weekly shot from a pen. You start low and ramp up over 16-20 weeks. The slow ramp cuts gut side effects.

What Is Tirzepatide?

Tirzepatide is a dual GIP/GLP-1 agonist. It is the first of its kind for weight loss. Lilly made it.

It activates two incretin hormone receptors at once:

• GLP-1 receptors — the same pathway as semaglutide (appetite reduction, gastric slowing).
• GIP receptors — a second gut hormone that plays a role in energy metabolism and insulin sensitivity.

This dual mechanism is the central reason researchers believe tirzepatide produces greater average weight loss.

Brand Names

• Mounjaro — injectable tirzepatide, FDA-approved for type 2 diabetes (2022).
• Zepbound — injectable tirzepatide, FDA-approved for chronic weight management (2023); also approved for moderate-to-severe obstructive sleep apnea (2024).

For weight loss comparison, Zepbound is the relevant formulation.

How Tirzepatide Works

Tirzepatide's GIP piece adds metabolic effects beyond semaglutide. GIP receptors are in fat tissue, not just the brain. Turning them on helps the body burn fat for fuel.

Some studies suggest GIP may also cut nausea. That could help patients tolerate higher doses.

Like semaglutide, tirzepatide is a weekly shot. You start at 2.5 mg and ramp up to a max of 15 mg.

Head-to-Head Weight Loss Results

This is the section most people come for. The data is genuinely striking. Trial design matters when comparing drugs studied in separate programs.

Semaglutide's Core Evidence: STEP Trials

The STEP program provided the pivotal data for Wegovy's approval. The key trials are:

• STEP-1 (NEJM 2021): Adults with obesity lost an average of 14.9% of body weight over 68 weeks on 2.4 mg semaglutide, vs 2.4% on placebo per Wilding et al. (NEJM 2021).
• STEP-3 (JAMA 2021): Combined with intensive behavioral therapy, semaglutide produced 16% weight loss over 68 weeks.
• STEP-4 (JAMA 2021): Patients who continued semaglutide maintained or extended weight loss; those switched to placebo regained two-thirds of lost weight within a year.

The STEP trials established Wegovy as a clinically meaningful tool. Roughly 86% of participants achieved ≥5% weight loss. About 32% achieved ≥20%.

Tirzepatide's Core Evidence: SURMOUNT Trials

The SURMOUNT program tested tirzepatide for weight loss in adults with obesity:

• SURMOUNT-1 (NEJM 2022): Adults without diabetes on 15 mg tirzepatide lost an average of 20.9% body weight over 72 weeks, vs 3.1% on placebo per Jastreboff et al. (NEJM 2022). About 57% achieved ≥20% weight loss.
• SURMOUNT-2 (Lancet 2023): Adults with type 2 diabetes lost 14.7% over 72 weeks on 15 mg, vs 3.2% on placebo per Garvey et al. (Lancet 2023).

These results are remarkable. The 20.9% figure represents the highest sustained weight loss any FDA-approved obesity drug has produced in trials.

The Direct Head-to-Head: SURMOUNT-5

In December 2024, SURMOUNT-5 in NEJM directly pitted the two drugs against each other. It was the first big head-to-head.

Adults with obesity got max-tolerated doses of each for 72 weeks. Tirzepatide hit 20.2% mean weight loss. Semaglutide hit 13.7%.

Tirzepatide users lost 47% more total body weight. The trial settled the question.

Side Effects: A Real Comparison

Both drugs share most side effects. GLP-1 drives the bulk of them. Tirzepatide's GIP piece tweaks the mix a bit.

Common Side Effects (Both Drugs)

Mild to moderate GI symptoms are most common:

• Nausea (30-45% of users in clinical trials)
• Diarrhea (20-30%)
• Constipation (15-25%)
• Vomiting (10-15%)
• Indigestion and reflux (10-15%)

Most are concentrated in the first 8-12 weeks during titration. They tend to improve as the body adapts.

Serious Risks (Both Drugs)

Both FDA labels carry boxed warnings for thyroid C-cell tumors. The basis is rodent data. Real-world data has not shown the same risk in humans, but the warning stays.

Other risks include rare pancreatitis (<1% in trials) and gallbladder events (3-5% with fast weight loss). Patients with MEN2 or a history of medullary thyroid cancer should not take either drug per FDA labeling (2026).

Tirzepatide-Specific Tolerability

Some trial and clinic data suggest tirzepatide may bring less nausea at matched doses. The GIP piece seems to dampen those pathways.

Real-world data from telehealth shows similar drop-out rates. About 5-7% of patients quit either drug due to side effects.

Cost Comparison in 2026

Cost is often the deciding factor. Both drugs have evolved pricing rapidly in 2025-2026.

List Prices and Cash-Pay Programs

Source	Wegovy (semaglutide)	Zepbound (tirzepatide)
Manufacturer list price	$1,350-$1,400/mo	$1,060-$1,300/mo
Direct cash-pay program	NovoCare: $349-$499/mo	LillyDirect: $399-$549/mo
Telehealth (insured)	$25-$75 with copay card	$25-$75 with copay card
Compounded (gray zone)	Mostly illegal in 2026	Mostly illegal in 2026

See our deep-dive on compounded GLP-1s after the FDA crackdown for the regulatory background.

Insurance Coverage

Coverage varies. The KFF 2026 Employer Health Benefits Survey found 38% of large plans cover Wegovy for obesity and 41% cover Zepbound. Both jumped from ~27% in 2024.

For type 2 diabetes (Ozempic and Mounjaro), coverage runs ~89-92%. If you have a diabetes diagnosis, insurance likely covers either drug for that use.

Which Should You Choose?

The honest answer: it depends. Here is the practical decision framework based on 2026 evidence.

Choose Tirzepatide (Zepbound) If:

• You want the highest probability of significant weight loss
• You have not tried a GLP-1 before
• Your insurance covers Zepbound or you can afford LillyDirect cash-pay
• You have obstructive sleep apnea (Zepbound is FDA-approved for this)
• You tolerated semaglutide poorly due to nausea

Choose Semaglutide (Wegovy) If:

• Your insurance covers Wegovy but not Zepbound
• You are already on Ozempic for diabetes and want to consolidate
• Cost is a primary factor and NovoCare's $349 starter dose works for you
• You have cardiovascular disease — semaglutide has the longest CV outcomes evidence (SELECT 5-year NEJM 2026)

When the Difference Matters Less

If you have 30-50 lbs to lose and respond well to either drug, the practical difference is small. Both will get you there. Cost, insurance, and physician familiarity should drive the decision.

For patients targeting 75+ lb loss or BMI 40+, tirzepatide's larger average effect is more meaningful clinically.

Cardiovascular and Metabolic Outcomes Beyond Weight

Both drugs deliver more than weight loss. The cardiovascular data is the strongest argument for chronic use.

Semaglutide Cardiovascular Evidence

The SELECT trial 5-year follow-up in NEJM (March 2026) showed 20% fewer heart events on continuous semaglutide. The benefit faded in patients who stopped before year 3.

The FLOW trial in NEJM (2024) showed 24% slower kidney disease in diabetic patients on semaglutide. These data make Wegovy the better-backed choice for patients with heart or kidney issues.

Tirzepatide Cardiovascular Evidence

The SURPASS-CVOT trial in 2025 showed 18% fewer heart events on tirzepatide in T2D patients. Tirzepatide's heart data is newer but trending toward parity with semaglutide.

For sleep apnea, Zepbound is FDA-approved as of 2024. Wegovy is not. Patients with moderate-to-severe OSA may prefer tirzepatide for that reason alone.

Frequently Asked Questions

Which is more effective for weight loss in 2026?

Tirzepatide produces greater average weight loss than semaglutide. In the SURMOUNT-5 direct head-to-head trial, tirzepatide users lost 20.2% of body weight versus 13.7% for semaglutide users over 72 weeks — a 47% larger total loss per NEJM 2024. Tirzepatide also achieved this in less time on average, with 57% of trial participants hitting at least 20% weight loss versus 32% on semaglutide. For patients prioritizing maximum weight loss, tirzepatide is the better choice based on current evidence.

Is semaglutide safer than tirzepatide?

Both drugs have similar safety profiles. Real-world data from 2024-2026 has not shown meaningful safety differences between them. Both carry boxed warnings for thyroid C-cell tumors based on rodent studies (not confirmed in humans), and both can cause pancreatitis or gallbladder events in rare cases. Tirzepatide users report slightly less nausea on average due to GIP receptor modulation, but discontinuation rates are similar. Patients with MEN2 syndrome or a personal history of medullary thyroid cancer should avoid both drugs.

Can I switch from semaglutide to tirzepatide?

Yes, switching is common and clinically supported. Most providers recommend a 1-week washout period between the last semaglutide dose and the first tirzepatide dose. Starting tirzepatide at 2.5 mg is standard for patients new to GIP exposure, even if they tolerated high-dose semaglutide. The 2025 SURPASS-SWITCH trial found patients who switched from semaglutide to tirzepatide lost an additional 4.7% body weight over 52 weeks. Our switching guide walks through the protocol.

Which is cheaper out of pocket in 2026?

Costs are comparable. Wegovy via NovoCare starts at $349 a month for the starter dose and $499 for maintenance. Zepbound via LillyDirect starts at $399 for the 2.5 mg vial and reaches $549 for higher doses. With commercial insurance and savings cards, both can drop to $25-$75 a month at the pharmacy counter. Compounded versions used to be cheaper at $149-$299, but FDA enforcement in 2026 has effectively ended legal mass-market compounding per the FDA crackdown.

Do both drugs need to be continued long-term to keep the weight off?

Yes. Both semaglutide and tirzepatide require continued use for sustained weight loss. The STEP-4 trial showed that semaglutide patients switched to placebo regained two-thirds of lost weight within a year. The SURMOUNT-4 trial showed similar regain after stopping tirzepatide. Obesity medicine specialists treat obesity as a chronic disease requiring chronic treatment, just like hypertension or hyperlipidemia. See our cycling vs continuous use guide for the full evidence on long-term protocols.

The Bottom Line

Tirzepatide produces greater average weight loss than semaglutide in head-to-head data. That is the most important comparative finding.

For most patients targeting significant weight loss, tirzepatide (Zepbound) is the better choice in 2026. Semaglutide (Wegovy) remains a legitimate option, especially when insurance dictates the choice or when the patient is already on Ozempic for diabetes.

Both drugs require chronic use for sustained effect. Both have similar safety profiles. Both have transformed obesity treatment in ways that would have been hard to imagine five years ago.

Talk to your clinician about which drug fits your medical history, your insurance, and your goals. The answer is rarely one-size-fits-all.

Related Reading

• Compounded GLP-1s After the FDA Crackdown
• GLP-1 Cycling vs Continuous Use
• Best GLP-1 Telehealth Programs Ranked
• Best Alternatives to GLP-1 Medications

-- The GLP-1 Daily Team